The Epstein-Barr virus(EBV)-determined nuclear antigen (EBNA) was purified from a variety of EBV-carrying nonproducer cells. Antigen was detected by Western blotting and subsequent visualization of complexes with antiserum/protein A. All cell lines contained several EBNA components, ranging in molecular weight from 48,000 (48K) to 73K. Even higher-molecular-weight forms of EBNA-positive immunoreactivity were detected, but in much lower yield and in only some preparations (8IK in Raji; 120K in Namalva and Raji). Preparations in which the 48K, 65K, 70K, or 73K polypeptides predominated had amino acid compositions with largely similar distributions for most residues. The preparations also yielded similarly sized large fragments upon proteolytic treatments. These findings suggested that all structures are related and that the 48K component may be a part of, or a degradation product from, the larger 65–73K components.

Keywords:
Epstein-Barr virus, Nuclear antigens, Burkitt lymphoma, Lymphoblastoid cells, Epstein-Barr virus-determined nuclear antigen
This content is only available via PDF.
© 1983 S. Karger AG, Basel
1983
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.